The heart rarely gets top billing in cancer treatment stories. Tumors get the drama, T cells get the heroic montage, and the myocardium is off to the side like a dependable character actor waiting for one line and a decent sandwich. This paper argues that the heart deserves more attention, especially if it has already been through something rough.
Immune checkpoint inhibitors, including PD-1 blockers, work by taking the brakes off the immune system so it can attack cancer more aggressively. That has changed oncology in a very real way. But brakes exist for a reason, and sometimes when you cut them, the immune system does not stop neatly at the tumor. Sometimes it starts throwing elbows at healthy tissue too. The heart, inconveniently, is made of healthy tissue.
The Brake Pedal Is There for a Reason
PD-1 is one of the immune system's built-in restraint systems. It helps prevent T cells from getting too enthusiastic and mistaking "self" for "enemy." Block PD-1, and you can get a stronger anti-cancer response. Great for tumors. Less great if the immune system starts treating cardiac tissue like it crashed the wrong party.
That problem is uncommon, but not imaginary. A 2024 systematic review and meta-analysis in JAMA Oncology found cardiovascular adverse events and/or myocarditis in about 1.07% of patients in clinical trials, with myocarditis carrying outsized danger despite its rarity [2]. Rare is comforting right up until you are the rare one.
A Bruised Heart Keeps Receipts
The new study by Gergely and colleagues asks a smart question: what if the heart is not starting from zero? What if it has old damage, even damage that seemed to heal?
In the mouse part of the study, researchers first induced a reversible ischemic cardiac injury, basically giving the heart a past medical history. Months later, after cardiac function appeared to recover, they treated the mice with anti-PD-1. That is where things got ugly. Mice with prior ischemic injury developed worse cardiac dysfunction, more T-cell and macrophage infiltration, and a louder inflammatory signal than mice without that earlier injury [1]. Translation: the heart may look recovered, but it may still remember the insult like a grudge-holding aunt at Thanksgiving.
Then came the human data. The team looked at 1,671 cancer patients treated with PD-1 inhibitors. Of those, 109 developed new-onset heart failure over a median follow-up of 332 days. Patients with prior ischemic heart disease had higher odds of developing heart failure after starting PD-1 therapy, with an odds ratio of 2.11 in the matched analysis [1]. That is not a tiny wobble. That is a signal.
This Is Bigger Than One Scary Side Effect
Why does this matter? Because many cancer patients are older, many have cardiovascular risk factors, and a fair number already have some cardiac mileage on the engine. If prior ischemic injury raises the chance of trouble, then PD-1 therapy is not just an oncology story. It is a cardio-oncology story, which is a niche field with the deeply unfair job of cleaning up after two very dramatic organ systems.
This study also nudges the conversation beyond classic checkpoint myocarditis. When people hear about cardiac toxicity from immunotherapy, they often think of fulminant myocarditis, the headline-grabbing disaster. But the cardiovascular fallout can be broader: heart failure, arrhythmias, ischemic events, pericardial disease, and quieter forms of dysfunction that do not arrive waving a giant red flag [2,5]. Another 2024 mouse study similarly found that previous cardiovascular injury could prime the heart for lethal checkpoint inhibitor-associated myocarditis [4]. In other words, the heart may not need to be pristine for trouble to start. It may just need to be previously bruised.
The Part That Could Actually Change Care
The most practical takeaway is not "panic." It is "screen smarter."
If these findings hold up in more cohorts, patients starting PD-1 inhibitors with a history of ischemic heart disease may deserve closer cardiac surveillance. Not because immunotherapy is bad. It is not. It saves lives. But because "effective" and "harmless" are not the same word, and medicine gets into trouble when it pretends they are roommates.
The abatacept finding is also intriguing. In the mouse model, adding abatacept blunted the inflammatory response and preserved cardiac function [1]. That does not mean clinicians should start tossing abatacept around like confetti. It does mean there may be a future where we calm the heart without completely kneecapping the anti-cancer immune response. A 2024 Nature study adds to that hope by suggesting the immune response driving checkpoint myocarditis in the heart is distinct from the anti-tumor response, which raises the possibility of more selective treatment strategies down the road [3]. That would be a nice plot twist for once.
For now, this paper does something medicine badly needs more of: it respects history. Not just the patient's cancer history, but the heart's history too. Turns out the myocardium is not a blank slate. It is more like old wood - sturdy, useful, and very capable of showing where the fire passed through.
References
-
Gergely TG, Drobni ZD, Kovács T, et al. Inhibition of the PD-1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischemia. Cardiovasc Res. 2026. DOI: 10.1093/cvr/cvag085 | PubMed: 42019014
-
Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024;10(10):1390-1399. DOI: 10.1001/jamaoncol.2024.3065 | PMCID: PMC11342217
-
Blum SM, Zlotoff DA, Smith NP, et al. Immune responses in checkpoint myocarditis across heart, blood and tumour. Nature. 2024;636(8041):215-223. DOI: 10.1038/s41586-024-08105-5 | PubMed: 39506125
-
Rubio-Infante N, Castillo EC, Alves-Figueiredo H, et al. Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitor-associated lethal myocarditis in mice. ESC Heart Fail. 2024;11(2):1249-1257. DOI: 10.1002/ehf2.14614 | PMCID: PMC10966245
-
Suzuki Y, Kaneko H, Tamura Y, et al. Cardiovascular events after the initiation of immune checkpoint inhibitors. Heliyon. 2023;9(5):e16373. DOI: 10.1016/j.heliyon.2023.e16373 | PMCID: PMC10220239
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.